Cancer therapy with bispecific antibodies: Clinical experience

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 3, 2010, Pages 340-349

  Thakur, A ^a   Lum, L G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bispecific antibody; Cytotoxic T lymphocyte; Fc receptor; Immunotherapy; MAb; T cell; Targeted T cell; Tumor antigen

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; ANTIPYRETIC AGENT; BISPECIFIC ANTIBODY; BLINATUMOMAB; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CATUMAXOMAB; CD16 ANTIGEN; CD19 ANTIBODY; CD20 ANTIBODY; CD3 ANTIBODY; CD30 ANTIGEN; DEXAMETHASONE; ERTUMAXOMAB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; MDX 210; MDX 447; MDX H210; MELANOMA ASSOCIATED PROTEOGLYCAN; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; MT 103; MT 110; OKT 3; OVARIAN CANCER ASSOCIATED ANTIGEN; PETHIDINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ASCITES; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG MEGADOSE; DRUG STABILITY; DRUG TOLERABILITY; FOLLICULAR LYMPHOMA; GLIOMA; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; LOADING DRUG DOSE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MELANOMA; METASTASIS; NONHODGKIN LYMPHOMA; OVARY CANCER; OVARY CARCINOMA; PROSTATE CANCER; REVIEW; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; PROTEIN ENGINEERING; SINGLE-CHAIN ANTIBODIES;

EID: 77953188563     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP et al: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol (1996) 14(3):737-744.
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol (1999) 17(9):2639-2648.
3. Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgard L, Rebello P, Hale G, Waldmann H, Mellstedt H et al: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100(3):768-773.
4. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84(8):2457-2466.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 16(8):2825-2833.
6. Miller RA, Maloney DG, Warnke R, Levy R: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 306(9):517-522. (Pubitemid 12175745)
7. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 349(5):427-434.
8. Asano R, Ikoma K, Kawaguchi H, Ishiyama Y, Nakanishi T, Umetsu M, Hayashi H, Katayose Y, Unno M, Kudo T, Kumagai I: Application of the Fc fusion format to generate tag-free bispecific diabodies. FEBS J (2010) 277(2):477-487.
9. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA: Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a singlechain bispecific antibody. Int J Cancer (2002) 100(6):690-697.
10. Kufer P, Lutterbüse R, Baeuerle PA: A revival of bispecific antibodies. Trends Biotechnol (2004) 22(5):238-244.
11. Lindhofer H, Mocikat R, Steipe B, Thierfelder S: Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol (1995) 155(1):219-225.
12. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J et al: Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA (2006) 103(11):4005-4010.
13. Goldenberg DM, Rossi EA, Sharkey RM, McBride WJ, Chang CH: Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J Nucl Med (2008) 49(1):158-163.
14. Southam CM, Brunschwig A, Levin AG, Dizon QS: Effect of leukocytes on transplantability of human cancer. Cancer (1966) 19(11):1743-1753.
15. Damle NK, Doyle LV, Bradley EC: Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. J Immunol (1986) 137(9):2814-2822.
16. Grimm EA: Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality. Biochim Biophys Acta (1986) 865(3):267-279.
17. Lafreniere R, Rosenstein MS, Rosenberg SA: Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo. J Immunol Methods (1986) 94(1-2):37-49.
18. Merluzzi VJ, Smith MD, Last-Barney K: Similarities and distinctions between murine natural killer cells and lymphokine-activated killer cells. Cell Immunol (1986) 100(2):563-569.
19. Ortaldo JR, Mason A, Overton R: Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med (1986) 164(4):1193-1205.
20. Owen-Schaub LB, Abraham SR, Hemstreet GP 3rd: Phenotypic characterization of murine lymphokine-activated killer cells. Cell Immunol (1986) 103(2):272-286.
21. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA, Simpson C: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery (1986) 100(2):262-272.
22. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA et al: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 319(25):1676-1680.
23. Yang JC, Mule JJ, Rosenberg SA: Murine lymphokine-activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells. J Immunol (1986) 137(2):715-722.
24. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA (1994) 91(14):6458-6462.
25. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Natl Cancer Inst (1994) 86(15):1159-1166.
26. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
27. Kolb HJ, Holler E: Adoptive immunotherapy with donor lymphocyte transfusions. Curr Opin Oncol (1997) 9(2):139-145.
28. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 76(12):2462-2465.
29. Liu Z, Savoldo B, Huls H, Lopez T, Gee A, Wilson J, Brenner MK, Heslop HE, Rooney CM: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res (2002) 159:123-133.
30. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G: A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol (2003) 33(5):1334-1340.
31. P,Titus JA, Lotze MT, Cuttitta F, Longo DL, Groves ES, Rabin H, Durda PJ, Segal DM: Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody. J Immunol (1986) 137(7):2069-2072.
32. Raso V, Griffin T: Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res (1981) 41(6):2073-2078.
33. Segal DM, Garrido MA, Perez P, Titus JA, Winkler DA, Ring DB, Kaubisch A, Wunderlich JR: Targeted cytotoxic cells as a novel form of cancer immunotherapy. Mol Immunol (1988) 25(11): 1099-1103.
34. Titus JA, Perez P, Kaubisch A, Garrido MA, Segal DM: Human K/natural killer cells targeted with hetero-cross-linked antibodies specifically lyse tumor cells in vitro and prevent tumor growth in vivo. J Immunol (1987) 139(9):3153-3158.
35. Milstein C, Cuello AC: Hybrid hybridomas and their use in immunohistochemistry. Nature (1983) 305(5934):537-540.
36. Staerz UD, Bevan MJ: Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA (1986) 83(5):1453-1457.
37. Staerz UD, Bevan MJ: Targeting cells for attack by cytotoxic T lymphocytes using heteroconjugates of monoclonal antibodies. Symp Fundam Cancer Res (1986) 38:31-34.
38. Fendly BM, Kotts C, Vetterlein D, Lewis GD, Winget M, Carver ME, Watson SR, Sarup J, Saks S, Ullrich A, Shepard M: The extracellular domain of HER2/neu is a potential immunogen for active specific immunotherapy of breast cancer. J Biol Response Mod (1990) 9(5):449-455.
39. Balzar M, Winter MJ, de Boer CJ, Litvinov SV: The biology of the 17-1A antigen (Ep-CAM). J Mol Med (1999) 77(10):699-712.
40. Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer (1995) 72(4):928-933.
41. Canevari S, Mezzanzanica D, Mazzoni A, Negri DR, Ramakrishna V, Bolhuis RL, Colnaghi MI, Bolis G: Bispecific antibody targeted T cell therapy of ovarian cancer: Clinical results and future directions. J Hematother (1995) 4(5):423-427.
42. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H: Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer (2005) 117(3):435-443.
43. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH: Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA (2006) 103(18): 6841-6846.
44. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, Schlereth B et al: Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother (2007) 30(8):798-807.
45. Liu Y, Cheung LH, Marks JW, Rosenblum MG: Recombinant singlechain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor. Int J Cancer (2004) 108(4):549-557.
46. Liu Y, Zhang W, Cheung LH, Niu T, Wu Q, Li C, Van Pelt CS, Rosenblum MG: The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts. Neoplasia (2006) 8(5):384-393.
47. Huang TH, Morrison SL: A trimeric anti-HER2/neu ScFv and tumor necrosis factor-α fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther (2006) 316(3):983-991.
48. Rosenblum MG, Cheung LH, Liu Y, Marks JW 3rd: Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res (2003) 63(14):3995-4002.
49. Elsasser D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, van de Winkel JG, Stevenson GT, Glennie MJ, Gramatzki M: HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood (1996) 87(9):3803-3812.
50. Lewis LD, Cole BF, Wallace PK, Fisher JL, Waugh M, Guyre PM, Fanger MW, Curnow RT, Kaufman PA, Ernstoff MS: Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon ?: A multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods (2001) 248(1-2):149-165.
51. van Ojik HH, Repp R, Groenewegen G, Valerius T, van de Winkel JG: Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc γ RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer. Cancer Immunol Immunother (1997) 45(3-4):207-209.
52. Kroesen BJ, ter Haar A, Spakman H, Willemse P, Sleijfer DT, de Vries EG, Mulder NH, Berendsen HH, Limburg PC, The TH, de Leij L: Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cells. Cancer Immunol Immunother (1993) 37(6):400-407.
53. Nitta T, Sato K, Yagita H, Okumura K, Ishii S: Preliminary trial of specific targeting therapy against malignant glioma. Lancet (1990) 335(8686):368-371.
54. Ball ED, Guyre PM, Mills L, Fisher J, Dinces NB, Fanger MW: Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: Cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc γ RI (MoAb 32). J Hematother (1992) 1(1):85-94.
55. De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A, Phillips J, Clark M, Bast BJ: Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies. J Hematother (1995) 4(5):433-437.
56. Kroesen BJ, Nieken J, Sleijfer DT, Molema G, de Vries EG, Groen HJ, Helfrich W, The TH, Mulder NH, de Leij L: Approaches to lung cancer treatment using the CD3 x EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol Immunother (1997) 45(3-4):203-206.
57. Weiner LM, Clark JI, Davey M, Li WS, Garcia de Palazzo I, Ring DB, Alpaugh RK: Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc γ RIII. Cancer Res (1995) 55(20):4586-4593.
58. Weiner LM, Holmes M, Richeson A, Godwin A, Adams GP, Hsieh-Ma ST, Ring DB, Alpaugh RK: Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1. J Immunol (1993) 151(5):2877-2886.
59. Valone FH, Kaufman PA, Guyre PM, Lewis LD, Memoli V, Deo Y, Graziano R, Fisher JL, Meyer L, Mrozek-Orlowski M: Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. J Clin Oncol (1995) 13(9): 2281-2292.
60. James ND, Atherton PJ, Jones J, Howie AJ, Tchekmedyian S, Curnow RT: A phase II study of the bispecific antibody MDX-H210 (anti-HER2 x CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer (2001) 85(2):152-156.
61. Posey JA, Raspet R, Verma U, Deo YM, Keller T, Marshall JL, Hodgson J, Mazumder A, Hawkins MJ: A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies. J Immunother (1999) 22(4):371-379.
62. Baeuerle PA, Kufer P, Lutterbuse R: Bispecific antibodies for polyclonal T-cell engagement. Curr Opin Mol Ther (2003) 5(4): 413-419.
63. Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Riethmuller G, Gjorstrup P, Bargou RC: T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol (2003) 170(8):4397-4402.
64. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmuller G, Dorken B, Bargou RC: A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood (2000) 95(6):2098-2103.
65. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H et al: Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 321(5891):974-977.
66. Topp M, Goekbuget N, Kufer P, Zugmaier G, Degenhard E, Neumann S, Horst HA, Viardot A, Schmid M, Ottmann OG, Schmidt M et al: Treatment with anti-CD19 BiTE antibody blinatumomab (MT103/MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL): First results of an ongoing phase II study. Blood (2008) 112(Suppl):Abs 1926.
67. Baeuerle PA, Reinhardt C: Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res (2009) 69(12):4941-4944.
68. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H: The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer (2000) 83(2):261-266.
69. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H: Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol (1999) 163(3):1246-1252.
70. Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A et al: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Clin Cancer Res (2007) 13(13):3899-3905.
71. Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A, Korfel A, Jager M, Lindhofer H, Sommer H, Thiel E et al: Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res (2006) 12(10):3085-3091.
72. Sebastian M, Passlick B, Friccius-Quecke H, Jager M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A: Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Cancer Immunol Immunother (2007) 56(10):1637-1644.
73. TRION Pharma GmbH: EU approval for Removab: First trifunctional antibody hits market. Press Release (2009): April 23.
74. Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ: Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumabarmed activated T cells. Clin Breast Cancer (2003) 4(3):212-217.
75. Lum LG, Rathore R, Quesenberry PJ, Elfenbein GJ: Future prospects for patient care utilizing autologous lymphoid and hematopoietic stem cells. Med Health R I (2003) 86(8): 247-248.
76. Davol PA, Smith JA, Kouttab N, Elfenbein GJ, Lum LG: Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice. Clin Prostate Cancer (2004) 3(2):112-121.
77. Azuma M, Cayabyab M, Buck D, Phillips JH, Lanier LL: CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J Exp Med (1992) 175(2):353-360.
78. Donohue JH, Ramsey PS, Kerr LA, Segal DM, McKean DJ: Enhanced in vitro lysis of human ovarian carcinomas with activated peripheral blood lymphocytes and bifunctional immune heteroaggregates. Cancer Res (1990) 50(20):6508-6514.
79. Kerr L, Huntoon C, Donohue J, Leibson PJ, Bander NH, Ghose T, Luner SJ, Vessella R, McKean DJ: Heteroconjugate antibodydirected killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. J Immunol (1990) 144(10):4060-4067.
80. Phillips JH, Lanier LL: Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med (1986) 164(3):814-825.
81. Jung G, Martin DE, Muller-Eberhard HJ: Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. J Immunol (1987) 139(2):639-644.
82. Van Wauwe JP, Goossens JG, Beverley PC: Human T lymphocyte activation by monoclonal antibodies; OKT3, but not UCHT1, triggers mitogenesis via an interleukin 2-dependent mechanism. J Immunol (1984) 133(1):129-132.
83. Buter J, Janssen RA, Martens A, Sleijfer DT, de Leij L, Mulder NH: Phase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer. Eur J Cancer (1993) 29A(15):2108-2113.
84. Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation (1990) 49(4):697-702.
85. Chatenoud L, Ferran C, Reuter A, Legendre C, Gevaert Y, Kreis H, Franchimont P, Bach JF: Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-?. N Engl J Med (1989) 320(21):1420-1421.
86. Sosman JA, Weiss GR, Margolin KA, Aronson FR, Sznol M, Atkins MB, O'Boyle K, Fisher RI, Boldt DH, Doroshow J: Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: Clinical and immunologic effects. J Clin Oncol (1993) 11(8):1496-1505.
87. Janssen RA, Heijn AA, The TH, de Leij L: Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb. Cancer Immunol Immunother (1994) 38(1):53-60.
88. Lum LG, Rathore R, Dizon D, Wang D, Al-Kadhimi Z, Uberti JP, Ratanatharathorn V: Induction of immune responses and improved survival after infusions of T cells armed with anti-CD3 x anti-HER2/neu bispecific antibody in stage IV breast cancer patients (phase I). Blood (2007) 110(11 Pt 1): Abs 2747.
89. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA, Lum LG: Human T cells armed with HER2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res (2006) 12(2):569-576.
90. Lum LG, Davol PA, Lee RJ: The new face of bispecific antibodies: Targeting cancer and much more. Exp Hematol (2006) 34(1):1-6.
91. Reusch U, Sundaram M, Davol PA, Olson SD, Davis JB, Demel K, Nissim J, Rathore R, Liu PY, Lum LG: Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Clin Cancer Res (2006) 12(1):183-190.
92. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, Di Re EM, Eggermont AM, Goey SH, Gratama JW, Lamers CH, Nooy MA et al: Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst (1995) 87(19):1463-1469.
93. Link BK, Kostelny SA, Cole MS, Fusselman WP, Tso JY, Weiner GJ: Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. Int J Cancer (1998) 77(2):251-256.
94. Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, Schroen C, Atz J, Schmitt M: Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: A pilot clinical trial. Cancer Immunol Immunother (2007) 56(9):1397-1406.
95. Guo YJ, Che XY, Shen F, Xie TP, Ma J, Wang XN, Wu SG, Anthony DD, Wu MC: Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies. Nat Med (1997) 3(4):451-455.
96. Lum LG, Al-Kadhimi Z, Skuba C, Ratanatharathorn V, Uberti JP: Enhanced anti-breast cancer cytotoxicity after autologous peripheral blood stem cell transplant (PBSCT) by boosting with multiple infusions of activated T cells (ATC) armed with anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) prior to PBSCT. Blood (2007) 110(11 Pt 1):Abs 2748.
97. Hombach A, Tillmann T, Jensen M, Heuser C, Sircar R, Diehl V, Kruis W, Pohl C: Specific activation of resting T cells against CA19-9+ tumor cells by an anti-CD3/CA19-9 bispecific antibody in combination with a costimulatory anti-CD28 antibody. J Immunother (1997) 20(5):325-333. (Pubitemid 28011528)
98. Kuwahara M, Kuroki M, Arakawa F, Senba T, Matsuoka Y, Hideshima T, Yamashita Y, Kanda H: A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. nticancer Res (1996) 16(5A):2661-2667.
99. Compte M, Blanco B, Serrano F, Cuesta AM, Sanz L, Bernad A, Holliger P, Alvarez-Vallina L: Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther (2007) 14(4):380-388.
100. Bolhuis RL, Lamers CH, Goey SH, Eggermont AM, Trimbos JB, Stoter G, Lanzavecchia A, di Re E, Miotti S, Raspagliesi F et al: Adoptive immunotherapy of ovarian carcinoma with bs-mAbtargeted lymphocytes: A multicenter study. Int J Cancer Suppl (1992) 7:78-81.
101. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M: Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood (1997) 89(6):2042-2047. (Pubitemid 27132120)
102. Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM: Induction of adaptive anti-HER2/neu immune responses in a phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): A trial coordinated by the Eastern Cooperative Oncology Group. J Immunother (2007) 30(4):455-467.
103. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG: A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors. Cancer Immunol Immunother (2008) 57(2):155-163.